ProCE Banner Activity

Experts Answer Questions About Therapies Targeting BCMA and SLAMF7 in Multiple Myeloma

Clinical Thought

In this commentary adapted from a discussion at a live event during ASCO 2023, experts address questions about therapies targeting BCMA and SLAMF7 in multiple myeloma. 

Released: July 20, 2023

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Joseph Mikhael

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Noopur Raje

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Karyopharm Therapeutics, Legend Biotech USA Inc., and Pfizer Inc.

AbbVie Inc.

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics Inc.

Legend Biotech USA Inc.

Pfizer, Inc.

Program Director Disclosure

Program Director

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Joseph Mikhael, MD, MEd, FRCPC, FACP: consultant/advisor/speaker: Amgen, Bristol-Myers Squibb, Janssen, Karyopharm, Sanofi, Takeda.

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD: consultant/advisor: AbbVie, Amgen, Antengene, Arcellx, AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, Janssen, K36, Loxo Oncology, Oncopeptides, Pfizer, Roche-Genentech, Sanofi, Secura Biotherapeutics, Takeda; researcher: AbbVie, Allogene, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, GSK, Janssen, Regeneron, Roche-Genentech, Takeda. 

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Caribou, Jannsen, Immuneel, Pfizer; researcher: 2Seventy Bio, Pfizer.